Muscle wasting and weakness such as cachexia, atrophy, and sarcopenia are characterized by marked decreases in the protein content, myonuclear number, muscle fiber size, and muscle strength. This chapter focuses on the recent advances of pharmacological approach for attenuating muscle wasting. A myostatin-inhibiting approach is very intriguing to prevent sarcopenia but not muscular dystrophy in humans. Supplementation with ghrelin is also an important candidate to combat sarcopenia as well as cachexia. Treatment with soy isoflavone, trichostatin A (TSA), and cyclooxygenase 2 (Cox2) inhibitors seems to be effective modulators attenuating muscle wasting, although further systematic research is needed on this treatment in particular concerning side effects.
CITATION STYLE
Sakuma, K., & Yamaguchi, A. (2018). Drugs of muscle wasting and their therapeutic targets. In Advances in Experimental Medicine and Biology (Vol. 1088, pp. 463–481). Springer New York LLC. https://doi.org/10.1007/978-981-13-1435-3_21
Mendeley helps you to discover research relevant for your work.